Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection
- PMID: 32533322
- PMCID: PMC7292244
- DOI: 10.1007/s00415-020-09986-y
Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection
Conflict of interest statement
Dr. Chaumont reports having received travel grant from PEPS development, Roche and Pfizer. Dr. Roze reports served on scientific advisory boards for Orkyn, Aguettant, Merz-Pharma; received honoraria for speeches from Orkyn, Aguettant, Merz-Pharma, Medday-Pharma, Everpharma, International Parkinson and Movement disorders Society; received research support from Merz-Pharma, Orkyn, Aguettant, Elivie, Ipsen, Everpharma, Fondation Desmarest, AMADYS, Fonds de Dotation Brou de Laurière, Agence Nationale de la Recherche; received travel grant from Vitalair, PEPS development, Aguettant, Merz-Pharma, Ipsen, Merck, Orkyn, Elivie, Adelia Medical, Dystonia Medical Research Foundation, International Parkinson and Movement disorders Society, European Academy of Neurology, International Association of Parkinsonism and Related Disorders. Dr. Couratier reports having received travel grant from Allergan, Novartis, Esai, UCB, Medtronic, Merck Serono, Biogen, LFB, Teva, Icomed, GSK, Genzyme, Aguettant, Cyberonics and Merz-Pharma. Dr. Lannuzel reports having received research support from France Parkinson, PSP France, Agence Nationale de la Recherche, Fonds Européen de DEveloppement Regional, French Ministry of Health, University Hospital of Guadeloupe, received honoraria for a speech from Association des Neurologues du Québec; received travel grant from Vitalair, PEPS development, Merz-Pharma, International Parkinson and Movement disorders Society. Dr. San-Galli, Dr. Martino, Dr. Carles, and Dr. Joguet report no disclosures.
Figures

References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous